Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.

Novartis is proud to share that TIME has recognized Victor Bultó and Thierry Diagana among the most influential people shaping the future of health. Learn more about what drives our honorees.

A Q&A with Bryan Laffitte, who leads a Novartis team that’s using the tools of genetic medicine to innovate new therapies for neuromuscular and neurodegenerative conditions.

Leprosy is one of the world’s oldest infectious diseases – yet there are still around 200,000 cases every year1. As the only supplier of multidrug therapy, in January 2026 Novartis renewed its partnership to provide the medicine via the WHO, protecting vital access to treatment.

I sometimes overlook what I’ve achieved or overcome to arrive at this point in my career. The opportunities I’ve embraced, the advice I’ve received and the heartfelt decisions I’ve made. So sharing my journey with you was an opportunity to pause and reflect, strengthening my belief that change is not always easy, but it can be very rewarding.

Novartis has acquired Kate Therapeutics to further enhance and strengthen our ongoing efforts to advance gene therapies for patients.

At Novartis, we are constantly pushing the limits of science to develop and deliver transformative medicines that fight disease and help people live life on their terms.

The current refugee crisis is one of the world's greatest humanitarian challenges. Svitlana shares her story of her journey to Novartis and how her work as part of the Giving and Volunteering team is opening the doors to refugees and other marginalized groups and allowing our people to make a difference by helping those who are most vulnerable.